KUROS announces allowance of European Patent for synthetic biomaterials
Kuros Biosurgery AG announced the allowance of European Patent Application 00910049 by the European Patent Office. This now allowed patent application is a key component of a broad portfolio of applications and patents designed to protect Kuros’ synthetic biomaterial (matrix) technologies and its product candidates which utilise this technology. This novel synthetic matrix platform is a key source of innovative products which will be important to Kuros’ future successful development
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The company’s product candidates are based on two different matrix technology platforms; synthetic or fibrin matrices. Kuros’ most advanced product candidate based on its synthetic technology is Kuros’ dural sealant product candidate (KUR-023) which is currently undergoing clinical evaluation in Europe. Kuros intends that this clinical study will enable CE marking in Europe.
Kuros’ most advanced products are based on a fibrin matrix and include KUR-111 and KUR-113 which have achieved positive results in Phase II trials for tibial plateau fractures and tibial shaft fractures respectively.
Mr. Didier Cowling, Chief Executive Officer at Kuros says: “Obtaining the notice of allowance for this European patent application further builds on Kuros’ proprietary position around its key synthetic matrix technology platform. This platform is the basis of a number of Kuros’ novel product candidates and strengthening the IP position around these candidates adds significant value”.
The now allowed claims cover broadly Kuros` proprietary method for forming biomaterials by nucleophilic addition mechanism starting from functionalized precursor components, such as functionalized PEGs. The claims cover the biomaterial (synthetic matrix), its method of production, kits for delivery and several uses. The allowance of the European application follows the grant of the US applications as patents no. US 7,744,912 and US 7,413,739 which were granted with similar broad claims, as well as the grant of the Canadian (CA 2,359,318), Mexican (MX 276585) and Australian (AU 773 914) applications.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Category:Lyases

Technetics - Freiburg im Breisgau, Germany
Biochrom appoints Sam Luke as the new Group Managing Director

Phase 1 BAFF CAR T clinical trial for patients with relapsed and refractory multiple myeloma underway at UH Seidman Cancer Center - Study is being done through an agreement between UH and start-up Luminary Therapeutics
Category:Sexual_conflict

The role of the tunnel
Proteome atlas for the tuberculosis pathogen

Going global - Stowers team reports genome-wide analysis of genes that drive cell division in a multicellular organism

In case of a black widow bite, what can you do? - New antibodies discovered – with fewer side effects and without animal testing
